Cargando…

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer

Persistent androgen receptor (AR) signalling is the main driver of prostate cancer (PCa). Truncated isoforms of the AR called androgen receptor variants (AR-Vs) lacking the ligand binding domain often emerge during treatment resistance against AR pathway inhibitors such as Enzalutamide. This review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Katie Joanna, Henry, Isla, Maylin, Zoe, Smith, Christopher, Arunachalam, Einthavy, Pandha, Hardev, Asim, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014620/ https://www.ncbi.nlm.nih.gov/pubmed/36937454 http://dx.doi.org/10.3389/fonc.2023.1129140

Ejemplares similares

Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease
por: Maylin, Zoe R, et al.
Publicado: (2021)

Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
por: Nicolescu, Radu Costin Bizga, et al.
Publicado: (2022)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
por: Kattan, Michael W., et al.
Publicado: (2020)

The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis
por: Zhao, Shankun, et al.
Publicado: (2023)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jiaxin, et al.
Publicado: (2020)

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
por: Wang, Zhize, et al.
Publicado: (2020)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
por: Uo, Takuma, et al.
Publicado: (2020)

Ceramide Regulates Anti-Tumor Mechanisms of Erianin in Androgen-Sensitive and Castration-Resistant Prostate Cancers
por: Trapika, I Gusti Md Gde Surya C., et al.
Publicado: (2021)

The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression
por: Gao, Lin, et al.
Publicado: (2022)

Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
por: Liu, Wei, et al.
Publicado: (2021)

Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2022)

Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response
por: Annels, Nicola E., et al.
Publicado: (2020)

Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis
por: Mulati, Yelin, et al.
Publicado: (2021)

Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients
por: Wang, Chao, et al.
Publicado: (2022)

Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
por: Chirra, Martina, et al.
Publicado: (2019)

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis
por: Khan, Tanzila, et al.
Publicado: (2022)

Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol
por: Clark, Emma, et al.
Publicado: (2019)

LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models
por: Regufe da Mota, Sergio, et al.
Publicado: (2018)

Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer
por: Naiki-Ito, Aya, et al.
Publicado: (2020)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer
por: Jones, Dominic, et al.
Publicado: (2015)

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into “Low-” and “High-Risk” Categories for Prostate Cancer
por: McNally, Christopher J., et al.
Publicado: (2022)

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
por: Shimizu, Yasuomi, et al.
Publicado: (2018)

The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis
por: Liu, Rui-Ji, et al.
Publicado: (2021)

Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer
por: Ashizawa, Takeshi, et al.
Publicado: (2022)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i4pus1psimqrdblupod4ifphv1